共 163 条
[1]
Erdmann F(2013)International trends in the incidence of malignant melanoma 1953–2008—are recent generations at higher or lower risk? Int J Cancer 132 385-400
[2]
Lortet-Tieulent J(2013)Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer (Oxford, England: 1990) 49 1374-1403
[3]
Schuz J(2015)Vital signs: melanoma incidence and mortality trends and projections—United States, 1982–2030 MMWR Morb Mortal Wkly Rep 64 591-596
[4]
Zeeb H(2009)Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 6199-6206
[5]
Greinert R(2011)Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2507-2516
[6]
Breitbart EW(2012)Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet (London, England). 380 358-365
[7]
Ferlay J(2014)Combined vemurafenib and cobimetinib in BRAF-mutated melanoma N Engl J Med 371 1867-1876
[8]
Steliarova-Foucher E(2014)Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma N Engl J Med 371 1877-1888
[9]
Lortet-Tieulent J(2015)Improved overall survival in melanoma with combined dabrafenib and trametinib N Engl J Med 372 30-39
[10]
Rosso S(2010)Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 711-723